In a novel case, the Court of Protection has endorsed the human administration of a potential treatment for sporadic CJD, before the product has undergone any clinical trials.

Bridget Dolan QC, instructed by the Official Solicitor, represented the incapacitous patient at the centre of this case. He is now to be the first human recipient of PRN100, a monoclonal antibody that has shown some promise in combatting this dreadful disease in earlier animal studies.